2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3000

Safety of the Knee Needle Arthroscopy: A Review of 1136 Procedures in 919 Patients
Abstract Number: 3001

Lumbar CT-Guided Steroid Infiltration on the Refractory Low Back Pain. Study of 258 Procedures in the Same Center
Abstract Number: 3002

Does Morbid Obesity Negatively Affect Patient Reported Outcomes Following Total Knee Arthroplasty?
Abstract Number: 3003

Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes
Abstract Number: 3004

The Choosing Wisely Initiative: Is It Complete?
Abstract Number: 3005

Development and Initial Validation of the “MH Score”, a New Diagnostic Tool That Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Abstract Number: 3006

IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Abstract Number: 3007

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
Abstract Number: 3008

Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium
Abstract Number: 3009

Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 3010

Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study
Abstract Number: 3011

Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Abstract Number: 3012

Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.
Abstract Number: 3013

Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Abstract Number: 3014

Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].